"Antigens, Neoplasm" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Proteins, glycoprotein, or lipoprotein moieties on surfaces of tumor cells that are usually identified by monoclonal antibodies. Many of these are of either embryonic or viral origin.
| Descriptor ID |
D000951
|
| MeSH Number(s) |
D23.050.285
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Antigens, Neoplasm".
Below are MeSH descriptors whose meaning is more specific than "Antigens, Neoplasm".
This graph shows the total number of publications written about "Antigens, Neoplasm" by people in this website by year, and whether "Antigens, Neoplasm" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 3 | 3 | 6 |
| 1995 | 3 | 3 | 6 |
| 1996 | 8 | 6 | 14 |
| 1997 | 10 | 5 | 15 |
| 1998 | 9 | 7 | 16 |
| 1999 | 6 | 11 | 17 |
| 2000 | 12 | 9 | 21 |
| 2001 | 16 | 22 | 38 |
| 2002 | 15 | 13 | 28 |
| 2003 | 11 | 18 | 29 |
| 2004 | 16 | 17 | 33 |
| 2005 | 19 | 19 | 38 |
| 2006 | 24 | 19 | 43 |
| 2007 | 19 | 16 | 35 |
| 2008 | 24 | 5 | 29 |
| 2009 | 13 | 9 | 22 |
| 2010 | 12 | 19 | 31 |
| 2011 | 15 | 14 | 29 |
| 2012 | 18 | 16 | 34 |
| 2013 | 15 | 12 | 27 |
| 2014 | 12 | 14 | 26 |
| 2015 | 13 | 15 | 28 |
| 2016 | 10 | 10 | 20 |
| 2017 | 14 | 10 | 24 |
| 2018 | 12 | 11 | 23 |
| 2019 | 13 | 13 | 26 |
| 2020 | 12 | 16 | 28 |
| 2021 | 13 | 7 | 20 |
| 2022 | 3 | 11 | 14 |
| 2023 | 4 | 9 | 13 |
| 2024 | 8 | 8 | 16 |
To return to the timeline,
click here.
Below are the most recent publications written about "Antigens, Neoplasm" by people in Profiles.
-
Longitudinal analysis of the gut microbiota during anti-PD-1 therapy reveals stable microbial features of response in melanoma patients. Cell Host Microbe. 2024 Nov 13; 32(11):2004-2018.e9.
-
NK Receptor Signaling Lowers TCR Activation Threshold, Enhancing Selective Recognition of Cancer Cells by TAA-Specific CTLs. Cancer Immunol Res. 2024 Oct 01; 12(10):1421-1437.
-
COMPREHENSIVE MOLECULAR PROFILING OF UVEAL MELANOMA EVALUATED WITH GENE EXPRESSION PROFILING, PREFERENTIALLY EXPRESSED ANTIGEN IN MELANOMA EXPRESSION, AND NEXT-GENERATION SEQUENCING. Retina. 2024 09 01; 44(9):1580-1589.
-
Breast cancer immunotherapy using scFv antibody-based approaches, a systematic review. Hum Immunol. 2024 Sep; 85(5):111090.
-
Personalized neoantigen vaccines as early intervention in untreated patients with lymphoplasmacytic lymphoma: a non-randomized phase 1 trial. Nat Commun. 2024 Aug 11; 15(1):6874.
-
Gemogenovatucel-T (Vigil): bi-shRNA plasmid-based targeted immunotherapy. Future Oncol. 2024; 20(29):2149-2164.
-
15-Gene Expression Profile and PRAME as Integrated Prognostic Test for Uveal Melanoma: First Report of Collaborative Ocular Oncology Group Study No. 2 (COOG2.1). J Clin Oncol. 2024 Oct; 42(28):3319-3329.
-
Neoantigen-specific cytotoxic Tr1 CD4 T cells suppress cancer immunotherapy. Nature. 2024 Aug; 632(8023):182-191.
-
First-in-human dose escalation trial to evaluate the clinical safety and efficacy of an anti-MAGEA1 autologous TCR-transgenic T cell therapy in relapsed and refractory solid tumors. J Immunother Cancer. 2024 Jul 22; 12(7).
-
Pan-cancer proteogenomics expands the landscape of therapeutic targets. Cell. 2024 Aug 08; 187(16):4389-4407.e15.